Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin

• Published in: Clinical pharmacokinetics Vol. 61; no. 3; pp. 363 - 374
• Main Authors: Molina, Kyle C., Miller, Matthew A., Mueller, Scott W., Van Matre, Edward T., Krsak, Martin, Kiser, Tyree H.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-03-2022; Springer Nature B.V
• Subjects: Anti-Bacterial Agents; Antibiotics; Antimicrobial agents; Biosynthesis; Experiments; FDA approval; Humans; Internal Medicine; Lipoglycopeptides; Lungs; Medicine; Medicine & Public Health; Microbial Sensitivity Tests; Pharmacodynamics; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Proteins; Review Article; Streptococcus infections; Teicoplanin - analogs & derivatives; Teicoplanin - pharmacology; United States > US
• ISSN: 0312-5963; 1179-1926
• DOI: 10.1007/s40262-021-01088-w

Dalbavancin is a synthetic lipoglycopeptide that exerts its antimicrobial activity through two distinct modes of action, inhibition of cell wall synthesis and an anchoring mechanism. Compared with previous glycopeptide antibiotics, dalbavancin demonstrates improved antibacterial potency against Gram-positive organisms and a long half-life of approximately 1 week, which is longer in tissues (e.g., skin, bone) than plasma. These factors facilitated the development of single-dose or once-weekly dosing regimens to treat acute bacterial skin and skin structure infections (ABSSSI). Dalbavancin exhibits dose-proportional pharmacokinetics and is highly protein bound (93%). Despite being highly protein bound, it has a steady-state volume of distribution >10 L and distributes widely into the skin, bone, peritoneal space, and epithelial lining fluid, but not cerebrospinal fluid. Dalbavancin elimination occurs via a combination of renal (approximately 45%) and non-renal clearance, with dose adjustments recommended only in patients with a creatinine clearance <30 mL/min not receiving any form of dialysis. The established pharmacokinetic/pharmacodynamic index associated with bacterial kill is free area under the concentration-time curve over the minimum inhibitory concentration (
f
AUC/MIC), with a goal 24-h
f
AUC/MIC of at least 27.1 for
Staphylococcus aureus
infections. Recent data suggest usefulness in the treatment of infections beyond ABSSSI, with convenient dosing and redosing strategies for complicated infections requiring extended treatment durations. Additional studies are needed to confirm these preliminary findings.